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naire designed to measure the severity of the disease were analysed to assess
whether there was a difference between the treatment groups in terms of change
in severity over the 6 month period. METHODS: Latent Transition Analysis is used
to explain the responses to the questionnaire by grouping patients into categories
(severity groups) based on their responses. There are three parameters that can be
estimated using LTA; Membership probabilities (probability of belonging to a par-
ticular severity category); Transition probabilities (probability of moving to a par-
ticular severity category) and Item response probabilities. These parameters are
compared between the two treatment groups to determine if there is a difference
between them. Two covariates were included in the model to investigate their
effects. RESULTS: The analysis showed that there was no significant difference
between the treatment groups in terms of Membership probabilities or Transition
probabilities. One of the covariates was found to have a significant effect on the
responses. The effect of the covariate was different for the two treatment groups
and had an opposite effect on the Placebo group compared the effect on the Active
group. CONCLUSIONS: It has been shown that LTA can be a useful tool for analys-
ing multivariate ordinal data and that its application in clinical data analysis has
advantages over some of the more common techniques.
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OBJECTIVES: Treatment effects in survival analysis are often expressed as hazard
ratios (HR), which are not useful in cost-effectiveness analysis since they do not
entail units of health. Fortunately, parametric survival models can also be used to
estimate projected mean survival time (T). Two problems in survival analysis are
often misunderstood or ignored: non-collapsibility and omitted-variable bias due
to censoring. Non-collapsibility exists when the treatment effect changes as prog-
nostic covariates are added to the regression model, even when confounding is
absent (e.g. in a randomized controlled trial (RCT)). While HRs are known to be
non-collapsible, it has not yet been demonstrated whether non-collapsibility af-
fects T. Censoring induces bias when it is associated with patient characteristics
and no adjustment is undertaken. The objectives of this study were to disentangle
the effects of non-collapsibility and censoring bias and assess their impact on
estimates of T. METHODS: Survival, treatment and five normally distributed prog-
nostic covariates were simulated in RCT-like datasets with and without censoring.
Weibull regression models with an increasing number of covariates were used to
calculate the HR for treatment and T. RESULTS: For uncensored data, HRs de-
creased with the inclusion of additional covariates, while T remained constant. For
the censored data, T increased sharply with the inclusion of additional covariates,
while the HRs decreased. The estimates of the full model of both outcome mea-
sures were close to the means from the dataset, although the model was estimated
on censored data. CONCLUSIONS: Analysis of the synthesized data makes it pos-
sible to distinguish between the impact of non-collapsibility and censoring on HR
and T. While the HR is non-collapsible, T is collapsible. It can be used in cost-
effectiveness analysis, as long as all important prognostic factors are included in
the regression. The latter is a weakness of currently common analyses of RCT data.
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OBJECTIVES: To explore and quantify the extent to which the terms “efficacy” and
“effectiveness” are used consistently and correctly in and Health Technology As-
sessments (HTAs). Efficacy describes a drug’s effect in ideal and controlled circum-
stances (i.e. in clinical trials). Effectiveness describes the success of a drug in usual
or “real world” practices in which all conditions cannot be controlled. Effectiveness
is much more difficult to assess and is often measured by observational studies or
calculated by a meta-analysis of clinical trial results. METHODS: We examined 38
HTAs published from 2005-2011 covering 13 disease conditions from 6 agencies
(AHRQ, DERP, CADTH, IQWiG, NICE, and NHS Scotland), which included 115 phar-
maceutical products. We categorized each HTA based on whether their stated main
objective was to measure either clinical efficacy or clinical effectiveness. These
stated main objectives were then compared to the evidence actually evaluated in
the reported studies (ie. RCTs and/or observational studies). We quantified and
analyzed discrepancies between the stated objectives and actual objectives.
RESULTS: Of the 38 HTAs, 37 evaluated efficacy and 1 focused on effectiveness.
Eighteen reviews (47%) described their main objective, efficacy or effectiveness,
consistent with the actual evidence evaluated. Twenty reviews (53%) stated their
main objective was measuring clinical effectiveness, but presented evidence as-
sessing clinical efficacy. Of the 6 agencies, NICE and NHS Scotland showed the
highest percentages of discrepancies between stated objectives and evidence eval-
uated (80% and 100% respectively), while AHRQ and DERP had the lowest (0% and
29% respectively). CONCLUSIONS: Though the distinction between “efficacy” and
“effectiveness” is substantial, the terms are not always used appropriately or con-
sistently. Often, the uses of the terms in HTAs are misleading. This is a barrier to
clear communication, but the implications might be broader.
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OBJECTIVES: The Institute for Quality and Efficiency in Health Care (IQWiG) in
Germany evaluates benefits/harms and economic implications of medical inter-
ventions. For the purpose of cost-benefit analysis, IQWiG has developed the effi-
ciency frontier concept to determine the maximum reimbursable price for phar-
maceuticals. Within this concept benefits/harms are evaluated for each patient-
relevant endpoint. Methodological problems arise with the presence of multiple
patient-relevant endpoints because recommendations for the maximum reim-
bursable price will likely be imprecise. Conjoint analysis (CA) and analytic hierar-
chy process (AHP) are being discussed as potential approaches to aggregate multi-
ple patient-relevant endpoints. The objective of this contribution was to describe
both approaches and compare them with respect to their suitability as a method
for aggregating multiple patient-relevant endpoints within IQWiG’s efficiency
frontier concept. METHODS: A catalogue with criteria has been established to as-
sess both approaches with regard to their suitability for aggregating multiple pa-
tient-relevant endpoints. The catalogue comprises nine relevant legal and meth-
odological aspects: two criteria were identified based on legal requirements; three
criteria were included considering IQWiG method requirements; lastly, four gen-
eral methodological requirements were considered. RESULTS: Both methods were
assessed based on these criteria. Two criteria were identified that could be met by
both CA and AHP. The remaining seven criteria could be met by either CA or AHP.
None of IQWiG’s proposed approaches for prioritizing and weighting multiple pa-
tient-relevant endpoints could demonstrate to fulfill all relevant criteria when as-
sessed with regard to legal and methodological requirements. CONCLUSIONS:
With the presence of multiple patient-relevant endpoints the implementation of
the efficiency frontier concept remains unclear due to lack of methodological guid-
ance on how to aggregate multiple endpoints. There is substantial need for further
(empirical) research in methods for aggregating multiple patient-relevant end-
points.
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OBJECTIVES:During the last few years, there has been an increasing trend towards
more cost-effective monitoring of clinical trials and non-interventional studies.
Cost efficiencies can by gained with partial source data verification (SDV). The
impact of partial SDV on the accuracy of the data in these studies is unknown. In
order to propose an optimal level and method of partial SDV, we first need a better
understanding of the rates and types of discrepancies found while conducting SDV.
METHODS: PPD CRAs in NA and EMEA were invited to participate in an on-line
survey of 11 questions pertaining to level of SDV employed in studies and the
quantity/type of discrepancies found. PRELIMINARY RESULTS: Current response
rate to this survey is 28% (589/2094), with a completion rate of 83% (491/589). Only
26% (127/491) of the respondents report having used partial SDV, which was de-
fined as anything less than 100% SDV (“I always verify all of the data”). When asked
to estimate the average amount of discrepancy (all data fields) encountered be-
tween source data and CRF, two-thirds of the respondents report a typical burden
of 20% or less. Not surprisingly, the most common data discrepancies involve the
recoding of: concomitant medications (27%) followed by AEs and/or SAEs (20%). Of
those respondents who had experience with partial SDV, 32% (41/127) reported an
approach that combines ‘all data points within a subset of CRFs’ with ‘selected data
points in all CRFs’. When asked about their willingness to participate in a follow-up
interview with more detailed questions about experiences with SDV, 33% (163/491)
of the respondents answered ‘yes’. CONCLUSIONS: The results of this survey and
its planned follow-up survey will be helpful in evaluating optimal methods and
levels of partial SDV in both clinical trials and observational studies.
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OBJECTIVES: Acquisition of scientific data required for the rational decisions on
health policy has became an important tool in determining the validity of the
financing methods of treatment from public funds based on the health technology
assessment (HTA). The primary source of scientific evidence for health technology
assessment are randomized controlled trials (RCTs), because of their features (e.g.
randomization or blindness) reducing methodological bias. These features may
become a disadvantage, which markedly reduces the possibility of the transfer of
the results and conclusions to the everyday practice. In this situation an important
role begin to play pragmatic randomized controlled trials (PRCTs), providing highly
reliable information about the effectiveness in contrast to observational studies or
registries. However, an important problem is correct design and quality assess-
ment of such trials. METHODS: A systematic review in Medline through Pubmed
using the following queries: “(pragmatic OR practical OR naturalistic OR real world)
AND (design OR quality)” was performed till June 2012 to gather and systematize
the current information about pragmatic randomized trials to improve the quality
of the practical effectiveness evaluation in health technology assessment reports.
RESULTS: Using this search strategy nearly 28 000 hits were obtained. Preliminary
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evaluation of the found publications demonstrated that the best reflection of the
conditions of routine practice (generalizability) in PRCTs can be obtained mostly
through the development of broader inclusion criteria, minimizing the exclusion
criteria or broadening the scope of patients evaluation. We found also suitable
tools, which can be used both during the design and evaluation of reliability of
PRCTs: PRECIS, PR-tool, Pragmascope tool or CONSORT. CONCLUSIONS: Properly
assessed PRCTs data in conjunction with information about the efficacy from RCTs
will serve as a whole to facilitate business decisions in medical practice, as well as
health organizations and rationalization of cost-reimbursement of used or new
medical technologies.
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OBJECTIVES: Collecting patient data in longitudinal studies is often a concern in
terms of data accuracy and patient follow-up. Physician assessment alone might be
not sufficient or feasible. Multiple strategies can maximize patient retention. The
methods to achieve these goals are intensive and made even more complex in
global studies where regulatory requirements vary across individual countries. The
objective of this research is to summarize the means used to improve patient
retention. METHODS: The selected methods for patient retention have been used
for three ongoing longitudinal safety registries requested by the European Medi-
cines Agency and/or the Food and Drug Administration RESULTS: Three studies
were conducted to assess safety follow-up over 20, 10 and 6 years, one of them was
Pediatric and all were evaluating drugs in Inflammatory Bowel Disease area. A total
of 8, 000 children and 13,250 adults have to be enrolled by Gastroenterologists in 27
countries. Maintaining long-term interest from investigators is essential. This is
aided by careful site selection and training and provision of targeted study mate-
rials like patient profiles and newsletters as we as fair compensation. To mitigate
patient attrition, these studies implemented direct-to-patient contact. This strat-
egy minimizes loss-to-follow-up and enables data collection directly from the pa-
tients, increasing data quality. Data can be supplemented through additional con-
tacts with relatives/legal guardians and/or other Health Care Providers. This
methodology needs to be detailed in the protocol and study material to provide, to
patients and the regulatory bodies, a clear overview of the procedures and respon-
sibilities in each country. CONCLUSIONS: A correlation between good comprehen-
sion of the stakes and study procedures by the sites and patient retention is com-
monly established. However, specific actions which target maintaining patient
interest and commitment is also important to successful retention. The means
must be adapted to the design and the patient population.
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OBJECTIVES: The Institute for Quality and Efficiency in Health Care (IQWiG) in
Germany evaluates benefits/harms and economic implications of medical inter-
ventions. For the purpose of cost-benefit analysis, IQWiG has developed the effi-
ciency frontier concept to determine the maximum reimbursable price for phar-
maceuticals. Within this concept benefits/harms are evaluated for each patient-
relevant endpoint. If a compound shows additional/less benefit or less/more harm
in several aspects of benefit, the creation of several efficiency frontiers would be
required. The objective of this contribution was to assess whether the existence of
multiple patient-relevant endpoints is a common feature within benefit assess-
ments according to article 35a Social Code Book V which would entail multiple
efficiency frontiers. METHODS: IQWiG’s homepage was browsed for completed
benefit assessments. Between January 2011 and May 2012, 21 benefit assessments
were published by IQWiG. All assessments were screened in detail for information
on patient-relevant endpoints and endpoint-specific benefit assessments.
RESULTS: In 11 dossier assessments, benefit was endpoint-specifically assessed,
whereas in 10 assessments, no endpoint-specific assessment was performed.
Within the 11 dossier assessments, 19 subpopulations with endpoint-specific as-
sessments were identified. For each subpopulation, between one and five end-
points were assessed by IQWiG. In total, 50 patient-relevant endpoints were de-
tected. On average 2.63 patient-relevant endpoints per subpopulation were
assessed. CONCLUSIONS: Since benefits/harms are evaluated for each patient-
relevant endpoint the existence of multiple patient-relevant endpoints constitute a
challenge for the compilation of the efficiency frontier and the subsequent deter-
mination of the maximum reimbursable price. Recommendations will likely be
imprecise due to endpoint-specific benefits/harms. Prioritizing and weighting ben-
efit and harm aspects can therefore not be avoided within IQWiG’s proposed effi-
ciency frontier concept if the decision maker requires precise recommendations
for the maximum reimbursable price. Thus, an aggregation of benefit and harm
parameters into one single efficiency frontier is needed.
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OBJECTIVES: In investigator-based clinical trials, the use of placebo is often justi-
fied as it increases the probability from the peers’ expertise of 1/ gaining a public
grant; 2/ publishing results in higher-rank journals. METHODS: Among the 139
randomized clinical trials (RCT) evaluating drugs and currently managed by the
Paris Hospitals, 68 are placebo-controlled. Aim is to analyze the hurdles in obtain-
ing the placebo and its justification. RESULTS:Half of the studies had difficulties in
obtaining the placebo. In rare cases, the study was unfeasible. When the placebo
concerns a new drug, the company may accept to provide the drug and its placebo,
at the eventual expense for the institutional sponsor to provide all the data without
any further compensation. It may be considered as a disguised industrial sponsor-
ship, the institutional sponsor while taking the responsibility of the study, being
relegated to a role of a CRO. Obtaining a placebo of an old drug is trickier since the
company may not sell anymore its product and generic companies are not able
and/or interested to manufacture the placebo. The request of a manufacturer can
be so expensive (up to 200.000€) that is exceeds by far the price of the verum, and of
the grant. The rationale for using a placebo as comparator is to ensure a double-
blind. However, when the drug administration is short (e.g. emergency setting), or
when the endpoint is “hard” (i.e. mortality, imaging, biology), it is unlikely that any
placebo effect from subjects and/or investigators may impact the endpoint assess-
ment. In such situations, the comparator may be “no treatment” with whenever
possible a blind assessment. CONCLUSIONS: Placebo-controlled RCT are challeng-
ing for institutional sponsors. Investigators and methodologists when writing a
protocol and peers’ expertise of a grant or a publication submission should con-
sider the necessity and the feasibility of placebo.
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OBJECTIVE: To distinguish sensitivity analysis and uncertainty analysis, charac-
terize their differential roles in health economic decision making, and to provide
practical examples of their use and presentation in health economic analysis.
METHOD: The role of one-way sensitivity analysis is to quantify the impact of
varying a single parameter on the output of a model. However, this obscures an
important distinction between parameter uncertainty and variability. Sensitivity
analysis quantifies parameter variability in terms of the percentage change in a
model output for a given percentage change in a model input. Sensitivity is there-
fore an objective property of the model. Uncertainty analysis, on the other hand,
propagates a decision maker’s subjective parameter uncertainty through a model
to estimate the conditional uncertainty of the model output. Accordingly, the func-
tional role of sensitivity analysis is to help a decision maker to understand and
validate the internal model structure in order to gain trust in the model itself;
whereas the functional role of uncertainty analysis is to assess the potential impact
of a decision maker’s subjective parameter uncertainty on confidence in a partic-
ular model-based decision. These distinctive roles are both critical in health eco-
nomic analysis and decision making. We provide examples of sensitivity analysis
versus uncertainty analysis, show how to report the results of sensitivity and un-
certainty analyses, and discuss the implications of this distinction for conducting
one-way and probabilistic analyses. CONCLUSION: Confidence in model-based de-
cision making requires 1) confidence in the model itself, and 2) confidence in the
model output given one’s subjective parameter uncertainty. Sensitivity analysis
and uncertainty analysis, respectively, serve these differential roles.
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Three common methods of estimating optimal prices for pharmaceutical assets
are willingness-to-pay, health economic price appraisal, and reference price
benchmarking. PROBLEM: Each method has significant drawbacks. Willingness-to-
pay, assessed through primary research, can be limited by lack of knowledge of
product list prices and the disconnect between respondent answers and real-life
price acceptance. Health economic appraisals, utilizing cost-of-treatment models
to estimate the price at which new products are cost-effective, are subject to error,
interpretation, and are rarely accepted by stakeholders who drive price decisions.
Reference price benchmarking, using market analogues to gauge price points for
new products, does not take into account unique differences, perceived or real, of
assets. None of these methods are able to quantify market intangibles such as
unmet need and strength of competition. SOLUTION: To address these weak-
nesses, the authors have developed a mathematical framework using all three
pricing methodologies to triangulate on a price range. The Value-Based Pricing
Framework equation is a collection of activities that allows for the economic quan-
tification of an asset’s attributes, critical to determining an asset’s overall value-
based price. These activities include: 1) Willingness-to-pay Assessment: utilizes
qualitative and quantitative feedback from decision makers to understand price
expectations and thresholds vis-à-vis current competitors and comparators; 2)
Reference Price Benchmarking: Assesses pricing structure of comparators to pre-
dict performance; and 3) Health Economic Analysis: Estimates product pricing as a
function of health economic differentiation and determines cost-savings that can
be offset in price. CONCLUSION: Value-Based Pricing is a structured way of esti-
mating asset price based on its perceived value by various stakeholders. This flex-
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